Concomitant Eruptive Squamous Atypia and Bullous Drug Eruption Associated with Pembrolizumab
Main Article Content
Keywords
eruptive squamous atypia, bullous drug eruption, pembrolizumab
Abstract
This study involves the case of a rare eruptive squamous atypia (ESA) reaction and concurrent bullous eruption following pembrolizumab treatment for recurrent neck squamous cell carcinoma. This report aims to raise awareness to possible concurrent skin reactions related to PD-1 inhibitor treatment that has otherwise only been reported twice in melanoma patients.
References
2. Que SKT, Compton LA , Schmults CD. Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil. J Am Acad Dermatol 2019;81:111-22.
3. Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD , Lacouture ME. Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy. JAMA Dermatol 2017;153:694-7.
4. Fradet M, Sibaud V, Tournier E, Lamant L, Boulinguez S, Brun A et al. Multiple Keratoacanthoma-like Lesions in a Patient Treated with Pembrolizumab. Acta Derm Venereol 2019;99:1301-2.
5. Crow LD, Perkins I, Twigg AR, Fassett MS, LeBoit PE, Berger TG et al. Treatment of PD-1/PD-L1 Inhibitor-Induced Dermatitis Resolves Concomitant Eruptive Keratoacanthomas. JAMA Dermatol 2020;156:598-600.
6. Chaudhari S, Leon A, Levin E, Neuhaus I , Liao W. Case Report of Multiple Keratoacanthomas and Squamous Cell Carcinomas in a Patient Receiving Pembrolizumab. J Drugs Dermatol 2017;16:513-5.
7. Tembunde Y , Dika MN. Pembrolizumab-Induced Eruptive Keratoacanthomas and Lichen Planus in a Lung Cancer Patient. Cureus 2023;15:e43402.
8. Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M et al. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal of the American Academy of Dermatology 2018;79:1081-8.
9. Bandino JP, Perry DM, Clarke CE, Marchell RM , Elston DM. Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology. Journal of the European Academy of Dermatology and Venereology 2017;31:e378-e80.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.